Understanding Challenges and Needs in Refractory Chronic GVHD

Insights from 2023 ASH Annual Meeting
J

Clonal Hematopoiesis Is Common in Unrelated Stem Cell Donors but Has No Impact on Pt Outcome After SCT

By Insights from 2023 ASH Annual Meeting FEATURING Johannes Schetelig
By Insights from 2023 ASH Annual Meeting FEATURING Johannes Schetelig
45 views
December 29, 2023
0 Comments
Login to view comments. Click here to Login
06:18
Robert Zeiser

CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD

23:37
Rush University Medical Center

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Feat. E. Bhaimia
07:22
Giuseppe Francesco Milone

Steroid-Refractory GvHD Management: When to Switch From Steroids

46:03
University of Colorado Cancer Center

CAR NK Cells: Next Generation Cell Therapies for Cancer

Feat. K. Rezvani
08:08
Jose Perez Simon

Unmet Needs in GvHD and the Role of Axatilimab

08:43
Nandita Khera

Maintaining QoL in Chronic GvHD

17:18
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Approaches to Preventing and Treating GVHD in 2024

Feat. N. Hossain
14:19
Zachariah DeFilipp

Axatilimab in Chronic GVHD: Updates From the AGAVE-201 Study

27:21
UChicago Medicine

Updates in Transplantation and GVHD From Recent Meetings

Feat. M. Nawas
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
10:54
Insights from 2023 ASH Annual Meeting

Chronic GVHD: Results from Agave-201 - Axatilimab at 3 Different Dos…

Feat. D. Wolff